$SWKH
SWK Holdings Corp

2023 Q3 Form 10-Q Financial Statement

#000155278123000359 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $8.962M $9.497M
YoY Change -34.17% 36.8%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.200M $2.315M
YoY Change -26.42% -23.29%
% of Gross Profit
Research & Development $606.0K $1.509M
YoY Change -66.18% 1.96%
% of Gross Profit
Depreciation & Amortization $650.0K $637.0K
YoY Change 2.52% 1.76%
% of Gross Profit
Operating Expenses $606.0K $1.509M
YoY Change -66.18% 1.96%
Operating Profit $4.326M
YoY Change -35.98%
Interest Expense $176.0K $363.0K
YoY Change 114.63% 353.75%
% of Operating Profit 4.07%
Other Income/Expense, Net
YoY Change
Pretax Income $4.088M $5.388M
YoY Change -52.23% 621.29%
Income Tax -$386.0K $1.454M
% Of Pretax Income -9.44% 26.99%
Net Earnings $4.474M $3.934M
YoY Change -32.38% 596.28%
Net Earnings / Revenue 49.92% 41.42%
Basic Earnings Per Share $0.36 $0.31
Diluted Earnings Per Share $0.36 $0.31
COMMON SHARES
Basic Shares Outstanding 12.54M shares 12.82M shares
Diluted Shares Outstanding 12.58M shares 12.79M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.00M $6.805M
YoY Change 55.79% -87.76%
Cash & Equivalents $31.03M $6.805M
Short-Term Investments
Other Short-Term Assets $1.756M $1.885M
YoY Change 47.69% 37.99%
Inventory
Prepaid Expenses
Receivables $4.400M $4.381M
Other Receivables $0.00 $0.00
Total Short-Term Assets $37.20M $13.07M
YoY Change 30.66% -77.79%
LONG-TERM ASSETS
Property, Plant & Equipment $5.479M $5.598M
YoY Change -7.84% -7.79%
Goodwill $8.404M $8.404M
YoY Change 0.0% 0.0%
Intangibles $6.913M $7.339M
YoY Change -19.76% -18.83%
Long-Term Investments $100.0K $59.00K
YoY Change -97.21% -98.36%
Other Assets $4.057M $3.123M
YoY Change 125.14% 68.08%
Total Long-Term Assets $278.6M $277.4M
YoY Change 5.63% 22.96%
TOTAL ASSETS
Total Short-Term Assets $37.20M $13.07M
Total Long-Term Assets $278.6M $277.4M
Total Assets $315.8M $290.4M
YoY Change 8.07% 2.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.700M $2.966M
YoY Change -43.11% 6.84%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $22.00M $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.77M $2.996M
YoY Change 421.87% 7.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.312M $2.362M
YoY Change 49.74% 48.65%
Total Long-Term Liabilities $2.312M $2.362M
YoY Change 49.74% 48.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.77M $2.996M
Total Long-Term Liabilities $2.312M $2.362M
Total Liabilities $38.28M $16.56M
YoY Change 158.3% 28.41%
SHAREHOLDERS EQUITY
Retained Earnings -$4.148B -$4.152B
YoY Change -0.15% -0.2%
Common Stock $12.00K $12.00K
YoY Change -7.69% -7.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $277.6M $273.9M
YoY Change
Total Liabilities & Shareholders Equity $315.8M $290.4M
YoY Change 8.07% 2.12%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income $4.474M $3.934M
YoY Change -32.38% 596.28%
Depreciation, Depletion And Amortization $650.0K $637.0K
YoY Change 2.52% 1.76%
Cash From Operating Activities $3.800M $4.724M
YoY Change 121.96% -649.3%
INVESTING ACTIVITIES
Capital Expenditures $110.0K $183.0K
YoY Change -232.53% -445.28%
Acquisitions
YoY Change
Other Investing Activities -$30.00K $14.97M
YoY Change -99.92% 2.33%
Cash From Investing Activities -$140.0K $14.79M
YoY Change -99.62% 1.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.57M -15.95M
YoY Change -2810.14%
NET CHANGE
Cash From Operating Activities 3.800M 4.724M
Cash From Investing Activities -140.0K 14.79M
Cash From Financing Activities 20.57M -15.95M
Net Change In Cash 24.23M 3.561M
YoY Change -167.84% -74.04%
FREE CASH FLOW
Cash From Operating Activities $3.800M $4.724M
Capital Expenditures $110.0K $183.0K
Free Cash Flow $3.690M $4.541M
YoY Change 105.57% -662.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001089907
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q2 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
usd
CY2022Q2 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
usd
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
usd
us-gaap Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
usd
us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
usd
us-gaap Financing Receivable Allowance For Credit Losses Recovery
FinancingReceivableAllowanceForCreditLossesRecovery
usd
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39184
dei Entity Registrant Name
EntityRegistrantName
SWK Holdings Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0435679
dei Entity Address Address Line1
EntityAddressAddressLine1
5956 Sherry Lane
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 650
dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75225
dei City Area Code
CityAreaCode
972
dei Local Phone Number
LocalPhoneNumber
687-7250
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
SWKH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12540483 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6805000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6156000 usd
CY2023Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
4381000 usd
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
3094000 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1885000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1114000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
13071000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
10364000 usd
CY2023Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
11104000 usd
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
11846000 usd
CY2023Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
222950000 usd
CY2022Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
236555000 usd
CY2023Q2 us-gaap Derivative Instruments And Hedges
DerivativeInstrumentsAndHedges
2750000 usd
CY2022Q4 us-gaap Derivative Instruments And Hedges
DerivativeInstrumentsAndHedges
2750000 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
59000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
76000 usd
CY2023Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
25689000 usd
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
24480000 usd
CY2023Q2 swkh Warrant Assets
WarrantAssets
1459000 usd
CY2022Q4 swkh Warrant Assets
WarrantAssets
1220000 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7339000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8190000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
8404000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
8404000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5598000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5840000 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3123000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1742000 usd
CY2023Q2 us-gaap Assets
Assets
290442000 usd
CY2022Q4 us-gaap Assets
Assets
299621000 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2996000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3902000 usd
CY2022Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2445000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2996000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6347000 usd
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
11200000 usd
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
11200000 usd
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2362000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2145000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
16558000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
19692000 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12566519 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12566519 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12843157 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12843157 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
12000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12000 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4425991000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4430922000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4152119000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4151005000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
273884000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
279929000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
290442000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
299621000 usd
CY2023Q2 us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
9278000 usd
CY2022Q2 us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
6828000 usd
us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
18538000 usd
us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
17243000 usd
CY2023Q2 swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
183000 usd
CY2022Q2 swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
114000 usd
swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
301000 usd
swkh Pharmaceutical Development Revenue
PharmaceuticalDevelopmentRevenue
350000 usd
CY2023Q2 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
36000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
69000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
480000 usd
CY2023Q2 us-gaap Revenues
Revenues
9497000 usd
CY2022Q2 us-gaap Revenues
Revenues
6942000 usd
us-gaap Revenues
Revenues
18908000 usd
us-gaap Revenues
Revenues
18073000 usd
CY2023Q2 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
-682000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
-682000 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
363000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
80000 usd
us-gaap Interest Expense
InterestExpense
545000 usd
us-gaap Interest Expense
InterestExpense
160000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1509000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1480000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2228000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3381000 usd
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
637000 usd
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
626000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1285000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1330000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2997000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3018000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5537000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6178000 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
-4673000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
-1738000 usd
us-gaap Costs And Expenses
CostsAndExpenses
-9995000 usd
us-gaap Costs And Expenses
CostsAndExpenses
-7024000 usd
CY2023Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
399000 usd
CY2022Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-472000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-583000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-1165000 usd
CY2022Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-519000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-547000 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
316000 usd
us-gaap Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
502000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
5388000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
747000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
9914000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
5312000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1454000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
182000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1345000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1269000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
3934000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
565000 usd
us-gaap Profit Loss
ProfitLoss
8569000 usd
us-gaap Profit Loss
ProfitLoss
4043000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12741000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12835000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12787000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12833000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12785000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12885000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12830000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12882000 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
279929000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
35000 usd
CY2023Q1 swkh Effect Of Adoption Of Accounting Standard
EffectOfAdoptionOfAccountingStandard
-9683000 usd
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
531000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
4635000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
274385000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
164000 usd
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
4599000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
3934000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
273884000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
267236000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
85000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
3478000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
270799000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
166000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
565000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
271530000 usd
us-gaap Profit Loss
ProfitLoss
8569000 usd
us-gaap Profit Loss
ProfitLoss
4043000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
-682000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
156000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
113000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
168000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
29000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
1316000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
1257000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
583000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1165000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-547000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-516000 usd
us-gaap Amortization Of Deferred Loan Origination Fees Net
AmortizationOfDeferredLoanOriginationFeesNet
2297000 usd
us-gaap Amortization Of Deferred Loan Origination Fees Net
AmortizationOfDeferredLoanOriginationFeesNet
780000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
957000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
1599000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
199000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
251000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1285000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1330000 usd
us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
1287000 usd
us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
66000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
792000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
256000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-357000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2526000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5388000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3508000 usd
us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
13942000 usd
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
13101000 usd
us-gaap Payments To Acquire Finance Receivables
PaymentsToAcquireFinanceReceivables
25350000 usd
swkh Proceeds Repayment Of Finance Receivables
ProceedsRepaymentOfFinanceReceivables
3041000 usd
swkh Proceeds Repayment Of Finance Receivables
ProceedsRepaymentOfFinanceReceivables
34195000 usd
swkh Marketable Investment Principal Payment
MarketableInvestmentPrincipalPayment
17000 usd
swkh Marketable Investment Principal Payment
MarketableInvestmentPrincipalPayment
21000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
191000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
111000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3708000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8755000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
872000 usd
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-2445000 usd
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-8000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
5130000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8447000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
649000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12255000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6156000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42863000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6805000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55118000 usd
CY2023Q2 dei Entity Number Of Employees
EntityNumberOfEmployees
23 number
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zhjSHH8tWed3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zRA1LpJefP7i">Use of Estimates</span></i></b></span><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition; stock-based compensation; valuation of interest and accounts receivable; impairment of finance receivables; allowance for credit losses; long-lived assets; property and equipment; intangible assets; goodwill; valuation of warrants and other investments; contingent consideration; income taxes; and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Company’s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company’s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, health crises such as the COVID-19 global pandemic, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Company’s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"> </span></p>
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12885000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12830000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12882000 shares
CY2023Q2 us-gaap Profit Loss
ProfitLoss
3934000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
565000 usd
us-gaap Profit Loss
ProfitLoss
8569000 usd
us-gaap Profit Loss
ProfitLoss
4043000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12741000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12835000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12787000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12833000 shares
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
44000 shares
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
50000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
43000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
49000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12785000 shares
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
118000 shares
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
308000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
119000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
309000 shares
CY2023Q2 us-gaap Notes Receivable Gross
NotesReceivableGross
234054000 usd
CY2022Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
248401000 usd
CY2023Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
11104000 usd
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
11846000 usd
CY2023Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
222950000 usd
CY2022Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
236555000 usd
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
11846000 usd
CY2021Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
8388000 usd
us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
11846000 usd
us-gaap Financing Receivable Allowance For Credit Losses Recovery
FinancingReceivableAllowanceForCreditLossesRecovery
23000 usd
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-682000 usd
CY2023Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
11104000 usd
CY2022Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
8365000 usd
CY2023Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
222950000 usd
CY2022Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
236555000 usd
CY2023Q2 us-gaap Financing Receivable Excluding Accrued Interest Year One Originated Current Fiscal Year
FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear
4971000 usd
CY2023Q2 us-gaap Financing Receivable Excluding Accrued Interest Year Two Originated Fiscal Year Before Current Fiscal Year
FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear
76461000 usd
CY2023Q2 us-gaap Financing Receivable Excluding Accrued Interest Year Three Originated Two Years Before Current Fiscal Year
FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear
49585000 usd
CY2023Q2 us-gaap Financing Receivable Excluding Accrued Interest Year Four Originated Three Years Before Current Fiscal Year
FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear
30867000 usd
CY2023Q2 us-gaap Financing Receivable Excluding Accrued Interest Year Five Originated Four Years Before Current Fiscal Year
FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear
37996000 usd
CY2023Q2 us-gaap Financing Receivable Excluding Accrued Interest Originated More Than Five Years Before Current Fiscal Year
FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear
34174000 usd
CY2023Q2 us-gaap Financing Receivable Excluding Accrued Interest Before Allowance For Credit Loss
FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss
234054000 usd
CY2023Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
29850000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
22511000 usd
CY2023Q2 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
7339000 usd
CY2022Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
29850000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
21660000 usd
CY2022Q4 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
8190000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
900000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
900000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
851000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1546000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1076000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1076000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1076000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
1714000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7339000 usd
CY2022Q4 us-gaap Line Of Credit Facility Fair Value Of Amount Outstanding
LineOfCreditFacilityFairValueOfAmountOutstanding
2400000 usd
CY2023Q2 us-gaap Deferred Revenue
DeferredRevenue
30000 usd
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
33000 usd
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
33000 usd
CY2023Q2 swkh Revenues Excluding Other Revenue
RevenuesExcludingOtherRevenue
9461000 usd
CY2023Q2 us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
36000 usd
CY2023Q2 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
-682000 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
363000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1509000 usd
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
637000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2997000 usd
CY2023Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
715000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1454000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
3934000 usd
CY2022Q2 swkh Revenues Excluding Other Revenue
RevenuesExcludingOtherRevenue
6942000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
80000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1480000 usd
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
626000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3018000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
182000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
565000 usd
swkh Revenues Excluding Other Revenue
RevenuesExcludingOtherRevenue
18839000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
69000 usd
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
-682000 usd
us-gaap Interest Expense
InterestExpense
545000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2228000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1285000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5537000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-81000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1345000 usd
us-gaap Profit Loss
ProfitLoss
8569000 usd
swkh Revenues Excluding Other Revenue
RevenuesExcludingOtherRevenue
17593000 usd
us-gaap Revenue Not From Contract With Customer Other
RevenueNotFromContractWithCustomerOther
480000 usd
us-gaap Interest Expense
InterestExpense
160000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3381000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1330000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6178000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-1712000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1269000 usd
us-gaap Profit Loss
ProfitLoss
4043000 usd

Files In Submission

Name View Source Status
0001552781-23-000359-index-headers.html Edgar Link pending
0001552781-23-000359-index.html Edgar Link pending
0001552781-23-000359.txt Edgar Link pending
0001552781-23-000359-xbrl.zip Edgar Link pending
e23352001.jpg Edgar Link pending
e23352_ex31-1.htm Edgar Link pending
e23352_ex31-2.htm Edgar Link pending
e23352_ex32-1.htm Edgar Link pending
e23352_ex32-2.htm Edgar Link pending
e23352_swkh-10q.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
e23352_swkh-10q_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
swkh-20230630.xsd Edgar Link pending
swkh-20230630_def.xml Edgar Link unprocessable
swkh-20230630_lab.xml Edgar Link unprocessable
swkh-20230630_pre.xml Edgar Link unprocessable
swkh-20230630_cal.xml Edgar Link unprocessable